Glucox Biotech AB
Glucox Biotech AB is a privately owned Stockholm based Swedish research company. On the basis of a favourable patent position, extensive experience in the development of medicines for metabolic diseases, and in collaboration with academic researchers and contract research organisations Glucox Biotech develops clinically applicable therapeutics for treatment of type 2 diabetes; hyperglycaemia, insulin resistance and resulting complications.
Glucox Biotech also explores new ideas for the prevention of cellular damage in ischemic stroke and heart infarction.
Per Wikström, CEO, PhD and founder of Glucox Biotech.
Per Wikström has many years of research experience in the pharmaceutical industry from Immunex in Seattle, Pharmacia and Pfizer, mainly in the field of metabolic disorders and projects related to insulin resistance.
Board of Directors
In addition to Per Wikström, the Company Manager, the Board of Directors includs Björn Sundeby as chairman of the board, Håkan Rosén, Johan Viberg and Alan Harris. Björn Sundeby is a major investors and share holder in Glucox Biotech AB.